Pulmonary Hypertension | Disease Landscape & Forecast | G7 | 2022

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality, and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs approved for PH are considerable, driven by premium pricing and the high propensity for polypharmacy. Although this market has become congested, commercial interest in PH remains high. The great need for more-efficacious and disease-modifying agents, as well as approved treatment options for unserved populations, fuels the opportunity in this space.

Questions answered

  • Novel agents such as United Therapeutics’ ralinepag, Merck & Co.’s sotatercept, Liquidia’s Yutrepia, and United Therapeutics / MannKind’s Tyvaso DPI are in late-phase development for the treatment of PH. What do interviewed thought leaders say about the advantages and disadvantages of these therapies? How will the launch of these agents affect prescribing decisions?
  • Generic formulations have launched for several key branded therapies in recent years. How have these launches impacted prescribing patterns? How have/will generic launches impact the uptake of entrenched and emerging branded therapies?
  • Great unmet need exists for the treatment of PH WHO groups 2, and 5. What are the other key unmet needs in PH? How likely are these unmet needs to be fulfilled within the forecast period?
  • Pulmonary arterial hypertension patients are normally prescribed PDE-5 inhibitors and/or ERAs as first-line therapy. What are the treatment guidelines for later lines of therapy? How do these vary between geographical regions?

Content highlights

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis / Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, Yutrepia, Tyvaso DPI, sotatercept, macitentan / tadalafil FDC.

Key companies mentioned: Actelion, United Therapeutics, Bayer HealthCare, GlaxoSmithKline, Gilead Sciences, Pfizer, MannKind Corporation, Merck & Co., Liquidia Technologies.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report

launch Related Market Assessment Reports